Monoclonal Antibody Therapeutics Market Report 2025

The monoclonal antibody therapeutics market size has grown rapidly in recent years. It will grow from $199.98 billion in 2024 to $224.62 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth during the historical period can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, expanded use in oncology treatments, growth in biopharmaceutical manufacturing, government support for biologics research, and the rising incidence of autoimmune disorders.

The monoclonal antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $354.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth anticipated in the forecast period can be attributed to the expansion of personalized medicine, a growing geriatric population, broader indications for approved monoclonal antibodies, rising healthcare expenditures, and increased awareness among healthcare professionals. Key trends expected during this period include the development of bispecific antibodies, advancements in hybridoma technology, the application of AI in antibody discovery, progress in glycoengineering, the adoption of continuous bioprocessing methods, and the use of gene editing tools to enhance antibody expression.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the monoclonal antibody therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy tissues, treating them as foreign threats. This results in chronic inflammation and tissue damage. Environmental changes, including greater exposure to pollutants and shifts in microbial environments, are believed to contribute to the growing number of autoimmune conditions by triggering abnormal immune responses in genetically susceptible individuals. Monoclonal antibody therapeutics offer targeted treatment by blocking specific immune pathways that cause inflammation and damage, which helps alleviate symptoms and slow disease progression. For example, in March 2023, a report from the Office for Health Improvement & Disparities, a UK government department, indicated that in 2022, 17.6% of individuals aged 16 and older reported having a long-term musculoskeletal condition, often associated with autoimmune disease, compared to 17% in 2021. This trend highlights the increasing demand for effective therapies and supports the growth of the monoclonal antibody therapeutics market.

Companies in the monoclonal antibody therapeutics sector are developing bispecific monoclonal antibodies to improve treatment outcomes by targeting two antigens or epitopes simultaneously. These specialized antibodies are engineered to bind to either two separate antigens or two distinct sites on the same antigen. In March 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, launched Vabysmo (faricimab-svoa), a bispecific monoclonal antibody developed to treat eye diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO). The drug targets both VEGF-A and Angiopoietin-2 (Ang-2), improving vascular stability and reducing fluid buildup in the retina. Its dual-action mechanism enables longer intervals between doses - up to four months, helping reduce the treatment burden for patients.

In February 2024, AbbVie Inc., a biopharmaceutical company based in the United States, formed a partnership with OSE Immunotherapeutics SA to develop a new monoclonal antibody therapy focused on chronic and severe inflammation. The collaboration centers on the development and commercialization of OSE-230, a monoclonal antibody designed to activate the ChemR23 receptor, which plays a role in resolving inflammation. The goal is to provide improved therapeutic outcomes for patients dealing with serious inflammatory diseases. OSE Immunotherapeutics SA is a biotechnology company based in France that specializes in creating innovative immunotherapies, including monoclonal antibodies, for cancer and autoimmune disorders.

Major players in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Arcus Biosciences, and Y‑mAbs Therapeutics.

North America was the largest region in the monoclonal antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in monoclonal antibody therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the monoclonal antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The monoclonal antibody therapeutics market consists of sales of murine monoclonal antibodies, humanized monoclonal antibodies, antibody-drug conjugates, anti-infective monoclonal antibodies, and immune effector cell engagers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The monoclonal antibody therapeutics market research report is one of a series of new reports that provides monoclonal antibody therapeutics market statistics, including monoclonal antibody therapeutics industry global market size, regional shares, competitors with a monoclonal antibody therapeutics market share, detailed monoclonal antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibody therapeutics industry. This monoclonal antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monoclonal antibody therapeutics are lab-engineered molecules designed to function as substitute antibodies that can specifically recognize and bind to antigens found on cancer cells, pathogens, or components of the immune system. These therapies are developed to neutralize disease-causing agents or deliver targeted treatments directly to affected cells, making them highly effective in addressing a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases.

The primary product types in monoclonal antibody therapeutics include naked antibodies, fusion proteins, antibody fragments, conjugates, and multi-specific antibodies. Naked monoclonal antibodies are lab-produced proteins that operate independently, without being linked to drugs or radioactive substances. These products are applied across various therapeutic areas, such as autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and more, for the treatment of conditions like cancer, autoimmune diseases, infections, and hematological disorders. The end users encompass a diverse group, including hospitals, private clinics, and research institutions.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.